ENLV, IL0011319527

Enlivex stock: Allocetra trial reports durable 12-month response

Published on 11/10/2026 at 13:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Enlivex stock is in focus after favorable 12-month Allocetra trial data in knee osteoarthritis. Phase 2b enrollment is still advancing.

Allocetra Trial Shows Durable Response

Enlivex reported favorable 12-month topline results from a Phase I/IIa Allocetra trial in knee osteoarthritis.
Among patients aged 64 and older, clinically meaningful response reached 79.2 percent with Allocetra versus 47.6 percent with placebo.
The Phase 2b study has randomized 135 of 182 planned patients, with six-month topline data expected by mid-2027.

ENLV, IL0011319527, Illustration mit AI erstellt.

Enlivex reported favorable 12-month topline data from a Phase I/IIa trial of Allocetra in knee osteoarthritis on Monday, November 2, 2026. The company said the treatment response remained durable, keeping attention on its clinical pipeline.

According to the Enlivex investor page, 79.2 percent of patients aged 64 and older achieved a clinically meaningful response after 12 months in the Allocetra group, compared with 47.6 percent in the placebo group. The company reported a p-value of 0.027 for the comparison.

Phase 2b Enrollment Continues

Enlivex also said on October 28 that 135 patients had been randomized and received the first injection in its Phase 2b trial. The study plans to enroll 182 patients at clinical sites in the United States and Europe, and six-month topline results are expected by mid-2027.

For investors, the Phase 2b study is the next scheduled clinical milestone. Its progress may determine whether the earlier response signal can be tested in a larger late-stage development program for age-related moderate-to-severe knee osteoarthritis.

Enlivex stock traded at 1.19 euros on Lang & Schwarz at 13:18 CET on Tuesday, November 10, 2026.